Article
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
All News
Article
Members of an FDA advisory panel were sharply divided as to whether avacopan, an oral small molecule inhibitor of the C5a receptor, was sufficiently safe and effective for treating antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Article
An FDA advisory panel will consider whether to recommend approval of an oral C5a inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, with agency staff raising questions over the "clinical meaningfulness" of key study data.
Article
Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.
Article
Medscape offers up an informative overview of the newly described syndrome called VEXAS discovered by researchers at the National Institutes of Health.
Dr. John Cush
Tweet
Blindness with Tocilizumab in GCA: Is it a Worry? Dr. David Liew ( @drdavidliew )
#EULAR2021
https://t.co/xokPqGMEyA https://t.co/NJ3PrFR6nF
Aurelie Najm
Tweet
Rheum alliance trainee survey (n=302):
87-96% report negative impact of COVID19 on Rheumatology training:
-outpatient clinics (79%)
-inpatient consultations (59%)
-formal teaching (55%)
-procedures (53%) and
-ultrasonography (36%)
#POS0051 @RheumNow #EULAR2021 @kristenyoung
David Liew
Tweet
So it comes down to the grand question: how on earth do we actually monitor disease activity??
"We still don't have a failsafe algorithm... relapse is both underdiagnosed & overdiagnosed" - @Sarah_L_Mackie
The challenge lots of good people are working on!
#EULAR2021 @RheumNow https://t.co/PUa6Ly1DQw
David Liew
Tweet
Drug-induced ANCA-associated vasculitis:
here are the ones to look for👇
- hydralazine
- PTU
- penicillamine
- thiamazole
- sofosbuvir
- minocycline
- carbimazole
(but then a few others floating about!)
VigiBase data POS0118 #EULAR2021 @RheumNow https://t.co/ujgJAJQeKY
Richard Conway
Tweet
Fascinating talk by Dr Tombetti on the potential use of arterial wall derived microvesicles collected from plasma as a means of non-invasive liquid biopsy in vasculitis @RheumNow #EULAR2021 Abstr#OP0056 https://t.co/Y6UO2mpjV0
Md Yuzaiful Md Yusof
Tweet
Do look out for Abst #OP0057 today 2/6/21 1645 CEST #EULAR2021. We propose a data-driven algorithm for #rituximab maintenance in #ANCA #vasculitis to avoid excessive retreatment and low IgG @RheumJArn @edvital P. Emery @LeedsMedHealth @LTHTResearch @LeedsHospitals @LeedsBRC https://t.co/XRR0NFnpMu
Richard Conway
Tweet
Dr Sanchez-Bilbao presents surprising data that tocilizumab may improve even permanent vision loss in GCA @RheumNow #EULAR2021 Abstr#OP0065 https://t.co/oFGNZ04oKr
David Liew
Tweet
Some interesting abstracts at #EULAR2021 today on monitoring GCA with:
- ultrasound
OP0055 https://t.co/0fqLIK5IPV
- PET/CT
OP0069 https://t.co/WQl9VaHR9E
OP0064 https://t.co/w7biFT6qy0
What do you believe is the most accurate measure of true disease activity in GCA? @RheumNow
Richard Conway
Tweet
Dr Arnold @Yuz6Yusof present on personalised rituximab retreatment in AAV. Interesting that naive B-cell repopulation at 6 months predicts better sustained response compared to absence @RheumNow #EULAR2021 Abstr#OP0057 https://t.co/cypyQVMeYz
Robert B Chao, MD
Tweet
IVIG pending FDA review for tx of dermatomyositis after ProDERM study. Do you use IVIG for tx of DM?
#EULAR2021 @RheumNow
Richard Conway
Tweet
Dr Ponte presenting on use of halo sign on TA US to monitor GCA disease activity. Seems good, present and increased in 16/17 (94.1%) cases of first disease relapse @RheumNow #EULAR2021 #AbstrOP0055 https://t.co/T6hKjkb4AT
Dr. John Cush
Tweet
Real world study of 21 GCA patients over age 80 yrs taking tocilizumab. (for GC-sparing in 14, relapsing Dz in 8, severity in 4, DMARD failure in 4). 8 [2–21] months post-TCZ, 67% were off GCs. AE included 4 Hi Chol, 3 SIE, 2 cytopenia, 1 hi LFTs https://t.co/ER0ROQw4ma
Dr. John Cush
Tweet
Genomic study of 1190 vasculitis pts & 11302 controls identfied a genetic variant, rs3743841, located in an intron of the NAGPA gene, reached genome-wide significance for Kawasaki (p= 8.06x10−10) and IgA vasculitis.(p= 1.25x10−7; OR 1.47 ) https://t.co/bUX5MdmOSM
Dr. John Cush
Tweet
News Feature: Avacopan for ANCA Vasculitis Goes in Front of the FDA
An FDA advisory panel will consider whether to recommend approval of an oral C5a inhibitor for ANCA-associated vasculitis.
https://t.co/66NSjbkE8Q https://t.co/9cR2lBASjz
Dr. John Cush
Tweet
Risk factors for Kawasaki disease in Taiwan compared 4197 KD pts to controls. KD was more common in Males (OR 1.47), older mothers (>35 y; OR, 1.18), and in multivariable analysis, maternal ankylosing spondylitis (OR 2.02). https://t.co/4qbddaYkqY
